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Aging of the human population is a key concern 
worldwide because of the associated social and medical 
problems. Important diseases related to aging include 
neurodegenerative conditions, such as Alzheimer’s 
disease, most of which are characterized by the 
formation of intracellular protein aggregates in neurons 
and neuronal loss. Individuals with such diseases 
exhibit various neural disorders including motor, 
cognitive, and behavioral dysfunction. Another disease 
that has traditionally been associated with aging is 
obesity, although this condition, together with its 
accompanying metabolic abnormalities, has recently 
also begun to affect younger individuals as a result of 
changes in diet and lifestyle and has become a serious 
public health problem worldwide. A link between these 
two types of disease has been postulated on the basis of 
their association with aging. Indeed, the possible 
relation between neurodegeneration and obesity in 
animal models or humans has been studied now for 
several decades. However, most such studies have 
focused on the possibility that obesity and related 
metabolic disorders  exacerbate  neurodegeneration  and  
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thereby promote cognitive decline and increase 
vulnerability to brain injury [1]. Few studies have 
addressed the possibility that neurodegeneration in the 
brain may cause obesity, as is suggested by the 
identification of hereditary neurodegenerative disorders 
associated with obesity such as Prader-Willi syndrome 
[2]. 
 
E4 as a new player in the ubiquitin-proteasome system 
 
A key focus of our research group has been the 
functions and underlying mechanisms of the ubiquitin-
proteasome system (UPS). The UPS plays an important 
role in the elimination of short-lived regulatory proteins 
[3], including those that contribute to such processes as 
the cell cycle, cellular signaling in response to 
environmental stress or extracellular ligands, 
morphogenesis, secretion, DNA repair, and organelle 
biogenesis [3-5]. The UPS pathway includes two key 
steps: covalent attachment of multiple ubiquitin 
molecules to the protein substrate and degradation of 
the ubiquitylated protein by the 26S proteasome 
An animal model manifesting neurodegeneration and obesity
 
Etsuo Susaki
1,2 and Keiichi I. Nakayama
1,2 
 
1 Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3‐1‐1 
Maidashi, Higashi‐ku, Fukuoka, Fukuoka 812‐8582, Japan 
2 CREST, Japan Science and Technology Agency, 4‐1‐8 Honcho, Kawaguchi, Saitama 332‐0012, Japan 
 
Key words: ubiquitin, mouse model, neurodegeneration, obesity 
Received: 06/27/10; accepted: 07/07/10; published on line: 07/08/10 
Corresponding author:   Keiichi I. Nakayama, MD/PhD ;      E‐mail: nakayak1@bioreg.kyushu‐u.ac.jp    
Copyright: © Susaki and Nakayama. This is an open‐access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited 
 
Abstract: Although the existence of a link between neurodegenerative diseases and obesity has been suggested, a causal
relation between neural degeneration and obesity has remained to be demonstrated experimentally. We recently showed
that neurodegeneration in the hypothalamic satiety center results in obesity in mice transgenic for E4B (also known as
UFD2a), a mammalian ubiquitin elongation factor (E4). Increased expression of E4B in neurons of the transgenic mice
results in the formation of ubiquitin‐positive aggregates similar to those apparent in many human neurodegenerative
diseases as well as in degeneration of hypothalamic neurons responsible for the regulation of food intake and energy
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ubiquitin to the target protein consists of several 
components that act in concert [3,6], including a 
ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and a ubiquitin-protein 
isopeptide ligase (E3). E3 is thought to be the 
component of the ubiquitin conjugation system that is 
most directly responsible for substrate recognition. In 
addition, a new type of ubiquitylation enzyme, a 
ubiquitin chain assembly factor (E4), was recently 
discovered and shown to be required for the degradation 
of certain types of substrate, including an artificial 
fusion protein with an NH2-terminal ubiquitin moiety, 
via a ubiquitin fusion degradation (UFD) pathway [7,8]. 
Ufd2 of Saccharomyces cerevisiae is the prototype E4 
enzyme. Ufd2 contains a conserved U-box domain, 
which appears to be an essential functional domain for 
E4 activity [9,10], and is associated with Cdc48 [8], 
which belongs to the large family of AAA-type 
ATPases that are thought to possess chaperone activity 
[11,12]. We have previously shown that mouse E4B 
(also known as UFD2a) is a homolog of yeast Ufd2, 
given that it contains a conserved U-box domain at its 
COOH-terminus and interacts with VCP, a mammalian 
ortholog of yeast Cdc48. These properties of E4B 
suggest that the association of AAA-type ATPases with 
Ufd2-like proteins that possess ubiquitylation activity 
has been conserved through evolution and may thus be 
functionally important [10,13]. 
 
The roles of E4B in vivo have remained largely 
unknown, however. E4B is expressed predominantly in 
neural tissues of adult mice [10], suggesting that it 
performs a neural-specific function. We found that E4B 
targets the pathological form of ataxin-3—in which 
abnormal expansion of a polyglutamine tract is 
responsible for spinocerebellar ataxia type 3 (SCA3) in 
humans—for ubiquitylation and degradation in 
mammalian cells as well as in a Drosophila 
melanogaster model of SCA3 [14]. Furthermore, we 
isolated FEZ1 (fasciculation and elongation protein zeta 
1), a protein implicated in neurite extension, as a 
binding partner of E4B [15]. FEZ1 is a mammalian 
homolog of Caenorhabditis elegans UNC-76, which is 
required for axonal bundling and elongation in the 
nematode [16], suggesting that a FEZ1-E4B system also 
participates in axonal outgrowth and fasciculation in 
mammals. Other groups also reported that UFD2a is 
implicated in the process of Wallerian degeneration of 
neurons [17,18]. Moreover, we showed that E4B+/– 
mice manifest axonal dystrophy in the nucleus gracilis 
as well as degeneration of Purkinje cells associated with 
endoplasmic reticulum stress, and that these animals 
develop a neurological disorder [13]. Mice nullizygous 
for E4B died in utero as a result of developmental 
defects in the heart, suggesting an additional role for 
E4B in developmental processes in this organ. In spite 
of these various observations, however, the precise 
physiological functions of this enzyme remained 
elusive. 
 
Neurodegeneration and obesity in mice transgenic 
for E4B 
 
During further studies to explore the roles of E4B, we 
discovered that overexpression of E4B in a neural cell 
line resulted in the formation of protein aggregates that 
were recognized by antibodies to ubiquitin as well as by 
those to p62, a marker of ubiquitin-associated 
aggregates. This phenomenon was also reproduced in 
E4B transgenic (Tg) mouse lines in which expression of 
the E4B transgene is controlled by the promoter of the 
gene for the mammalian prion protein [19] (Figure 1A). 
This aggregate formation is apparently dependent on the 
ubiquitylation activity of the enzyme, given that few 
such aggregates were detected in cells expressing 
E4B(ΔU), a truncated form of E4B that lacks the 
catalytic U-box domain (Figure 1A). In addition, an 
important feature of the aggregates is that they resemble 
ubiquitin- and p62-positive aggregates observed in 
many human neurodegenerative diseases or in mice 
with neurodegeneration resulting from defects in 
autophagy, another pathway for the clearance of cellular 
components [20,21]. 
 
The aggregate formation in E4B Tg mice was apparent 
specifically in certain hypothalamic nuclei. Among 
these nuclei, the aggregate-associated neuro-
degeneration was most obvious in the paraventricular 
nucleus (PVN). PVN neurons are activated by signaling 
downstream of food intake [22-25], and they function as 
a satiety center. Indeed, lesions in the PVN result in the 
development of hyperphagic obesity in rat [26]. 
Furthermore, neurodegeneration-associated gliosis was 
observed in the region adjacent to the PVN in the 
hypothalamus of E4B Tg mice (Figure 1B), indicating 
that ectopic expression of E4B results in the formation 
of ubiquitin-positive aggregates and associated 
pathological features characteristic of neurodegenera-
tive diseases [27]. 
 
Surprisingly, the E4B Tg mice were unequivocally obese 
(Figure 1C) and manifested increased lipid accumulation 
in tissues such as adipose tissue and the liver [27]. We 
investigated whether this obese phenotype was 
attributable to functional impairment of the hypothalamic 
satiety center. The animals exhibited increased food 
intake and decreased energy expenditure as well as 
several abnormal responses of the center to satiety input, 
indicating that  malfunction of  the  hypothalamic  satiety  
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center is responsible for the obese phenotype of the E4B 
Tg mice. Finally, we observed that the Tg mice 
manifested metabolic disorders seen in obese humans. 
 
On the basis of our observations, we proposed that the 
E4B Tg mouse is a new animal model for 
neurodegeneration-associated obesity that possesses 
several advantages. First, these animals spontaneously 
develop obesity and thus do not need to be fed a high-
fat diet. Second, they manifest abnormalities in the 
highly restricted area of the hypothalamic satiety center 
and thus exhibit pathological features similar to those of 
some other mouse models of obesity, such as ob/ob and 
db/db mice, in which the hypothalamic leptin circuit is  
impaired [28,29]. Third, only one allele of the E4B 
transgene is required for mice to develop obesity. 
Furthermore, the extent of obesity can be varied by 
selection of transgenic lines with different levels of 
expression or different numbers of alleles of the 
transgene (Figure 1C), whereas most other mouse 
models are loss-of-function mutants and therefore 
require homozygosity of the mutant allele for 
manifestation of the phenotype. Fourth, E4B Tg mice 
also develop leptin and insulin resistance, glucose 
intolerance, hypercholesterolemia, and hypoadipo-
nectinemia during progression of the obesity phenotype. 
These characteristics thus suggest that E4B Tg mice 
recapitulate the course of human obesity. 
 
Perspective 
 
Our genetic mouse model has also provided the first 
experimental demonstration that neurodegeneration can 
indeed result in obesity, suggesting that some cases of 
human obesity might be attributable to hypothalamic 
neurodegeneration in aged individuals without any other 
neural disorders including cognitive and behavioral 
dysfunction. Aberrant activity of E4B might be a 
possible cause of obesity and associated metabolic 
disorders in humans, a notion that is consistent with the 
localization of obesity-related genetic markers in the 
vicinity of the E4B gene locus [30,31]. Further analysis 
of E4B function, particularly through identification of 
its substrates, should provide greater insight into the 
pathological properties of the molecule. More generally, 
nonspecific neurodegeneration associated with aging 
might result in a tendency to become obese. Together, 
our findings with E4B Tg mice open a new field of 
research linking obesity and aging processes as 
represented by degeneration of neural tissue. 
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Figure  1.  E4B  transgenic  (Tg)  mice  as  a  new  obesity
model  with  hypothalamic  neurodegeneration.  (A)
Immunofluorescence analysis of the PVN region of 6‐month‐old
wild‐type (WT) or E4B(ΔU) Tg mice and of a 4‐month‐old E4B Tg
mouse.  Brain  slices  were  stained  with  antibodies  to
polyubiquitin (green) and to p62 (red), and nuclei were stained
with Hoechst 33258 (blue). Protein aggregates reacted with both
types of antibody in the PVN region of E4B Tg mice, but not in
that of WT or E4B(ΔU) Tg mice. (B) Immunofluorescence analysis
of  the  PVN  region  of  10‐week‐old  WT  or  E4B  Tg  mice  with
antibodies  to  glial  fibrillary  acidic  protein  (GFAP,  red).  Nuclei
were stained with Hoechst 33258 (blue). SCN and 3V indicate
the  suprachiasmatic  nucleus  and  third  ventricle,  respectively.
The number of GFAP‐positive glial cells in and around the PVN
was  increased  in  E4B  Tg  mice,  indicative  of  gliosis  associated
with neurodegeneration. (C) Obesity in E4B Tg mice. The gross
appearance  of  an  E4B  Tg  mouse  and  a  WT  littermate  at  9
months of age is shown on the left. The time course of body
weight (BW) for WT mice and E4B Tg lines harboring one or two
alleles  of  the  transgene  is  shown  on  the  right.  The  extent  of
obesity in the Tg animals harboring two alleles of the transgene
was about twice that in littermates harboring only one allele,
indicating that the obese phenotype is directly related to the
expression level of the transgene. *P < 0.05, **P < 0.01 for the
Tg line with two alleles of the transgene versus wild‐type mice. 
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